scholarly journals The IgE Blocking Activity Induced by Dermatophagoides pteronyssinus Subcutaneous Immunotherapy Does Not Correlate with Specific IgA but with IgG4 in both Serum and Saliva

2021 ◽  
pp. 1-14
Author(s):  
Yong He ◽  
Jinling Liu ◽  
Deyu Zhao ◽  
Suqin Zhang ◽  
Guodong Hao ◽  
...  
Keyword(s):  
Treatment Time ◽  
Symptomatic Treatment ◽  
Specific Ige ◽  
Dermatophagoides Pteronyssinus ◽  
Subcutaneous Immunotherapy ◽  
Control Group ◽  
Serum Igg4 ◽  
Specific Igg4 ◽  
Blocking Activity ◽  
Der P 2

<b><i>Background:</i></b> The role of salivary-specific IgG4 and IgA in subcutaneous immunotherapy (SCIT) is not well defined. We aimed to investigate the change of IgG4 and IgA in both serum and saliva and their correlations with IgE-blocking-factor (IgE-BF) during SCIT. <b><i>Method:</i></b> 307 <i>Dermatophagoides pteronyssinus</i> (DP) allergic rhinitis and/or asthma patients were recruited for this study. 286 patients received DP-SCIT for 1 year. Twenty-one patients received only symptomatic treatment. DP-, Der p 1-, and Der p 2-specific IgE in serum, specific-IgG4 and Der p 2-specific IgA1 and IgA2 in both serum and saliva were measured at timepoints 0, 4, and 12 months during DP-SCIT. Correlation between salivary and serological IgG4, IgA, and their correlation with DP-specific IgE-BF measured in serum was evaluated. <b><i>Results:</i></b> During DP-SCIT, the allergen-specific IgG4 in both saliva and serum increased and correlated significantly, the correlation becomes stronger over the treatment time. DP-specific IgE-BF significantly correlated with DP-specific IgG4 in serum (<i>p</i> &#x3c; 0.0001) at different timepoints and in saliva at 12 months of SCIT (<i>p</i> &#x3c; 0.01). No change in Der p 2-specific IgA during DP-SCIT was observed, and the IgA in serum did not correlate with IgA in saliva. There was no correlation between DP IgE-BF and Der p 2-specific IgA in serum or saliva. The control group did not exhibit significant changes in any antibody level measured. <b><i>Conclusion:</i></b> The IgE blocking activity induced by DP-SCIT treatment correlated with specific IgG4 and not IgA. The IgG4 in saliva correlates with serum IgG4 and can be an alternative immunological marker beyond 1 year of SCIT treatment.

scholarly journals Recent advances in allergic rhinitis

F1000Research ◽  
2018 ◽  
Vol 7 ◽  
pp. 1333 ◽  
Author(s):  
Flavia C. L. Hoyte ◽  
Harold S. Nelson
Keyword(s):  
Allergic Rhinitis ◽  
Work Productivity ◽  
Allergen Challenge ◽  
Economic Cost ◽  
Symptomatic Treatment ◽  
The United States ◽  
Specific Ige ◽  
Subcutaneous Immunotherapy ◽  
Nasal Allergy

Allergic rhinitis affects 20 to 30% of adults in both the United States and Europe and perhaps a somewhat higher percentage of children. In addition to nasal and ocular symptoms directly related to the allergic process, interference of these symptoms with sleep leads to daytime sleepiness and impaired quality of life. Patients miss work because of symptoms but an even greater problem is interference with work productivity, or presenteeism, which has been reported to be the biggest contributor to the total economic cost of allergic rhinitis. There has been increasing awareness that many patients with either seasonal or perennial symptoms but negative skin and in vitro tests for allergen sensitivity have local nasal allergy, diagnosable by the presence of allergen-specific IgE in their nasal secretions or a positive nasal allergen challenge or both. The pharmaceutical management of allergic rhinitis rests on symptomatic treatment with antihistamines that perhaps are more effectively administered intranasally than orally and intranasal corticosteroids. Allergen immunotherapy is very effective, even for local allergic rhinitis, and the shortcomings of subcutaneous immunotherapy of inconvenience and safety are reduced by the introduction of sublingual immunotherapy (SLIT). Use of the latter is currently somewhat limited by the lack of appropriate dosing information for SLIT liquids and the limited number of allergens for which SLIT tablets are available.

A sensitive reverse ELISA for the measurement of specific IgE to Der p 2, a major Dermatophagoides pteronyssinus allergen

2001 ◽  
Vol 86 (5) ◽  
pp. 545-550 ◽  
Author(s):  
Deise A.O. Silva ◽  
Aurélia M. Gervásio ◽  
Mônica C. Sopelete ◽  
Erika Arruda-Chaves ◽  
L.K. Arruda ◽  
...  
Keyword(s):  
Specific Ige ◽  
Dermatophagoides Pteronyssinus ◽  
Der P 2

Autologous enzyme-linked immunosorbent facilitated antigen binding detects IgE-blocking activity based on direct competition between allergen-specific IgE and non-IgE

Immunotherapy ◽  
2021 ◽  
Author(s):  
Haifeng Zhong ◽  
Xuxin Lai ◽  
Jing Li ◽  
Xiaoxiong Xiao ◽  
Shi Chen ◽  
...  
Keyword(s):  
Allergen Immunotherapy ◽  
Treatment Time ◽  
Specific Ige ◽  
Antigen Binding ◽  
Treatment Cessation ◽  
Time Points ◽  
Direct Competition ◽  
Blocking Activity ◽  
Kinetics Of ◽  
Time Point

Aim: To measure IgE-blocking activity induced by allergen immunotherapy (AIT) by an enzyme-linked immunosorbent facilitated antigen binding (ELIFAB) assay based on autologous immunoglobulin competition. Methods: The developed ELIFAB assay was used to investigate the kinetics of IgE-blocking activity in 87 patients at multiple AIT treatment time points, in comparison to the changes in IgG4. Results: High ELIFAB response was observed until 2.5 months of AIT, then significantly decreased after 4 months and remained suppressed during the 3-year AIT period. After treatment cessation, the ELIFAB response was maintained at the level seen at the 4–6 month treatment time point, similar to IgG4, indicating sustained IgE-blocking activity related to IgG4. Conclusion: This ELIFAB assay measures the IgE-blocking activity for autologous allergen-specific IgE and non-IgE during and after immunotherapy. It is suited for measuring the sustained IgE-blocking activity induced by AIT.

scholarly journals Allergen-Specific IgE and IgG4 as Biomarkers for Immunologic Changes during Subcutaneous Allergen Immunotherapy

Antibodies ◽  
2021 ◽  
Vol 10 (4) ◽  
pp. 49
Author(s):  
Georgi Nikolov ◽  
Yana Todordova ◽  
Radoslava Emilova ◽  
Diana Hristova ◽  
Maria Nikolova ◽  
...  
Keyword(s):  
Allergic Rhinitis ◽  
Allergen Immunotherapy ◽  
Specific Ige ◽  
Subcutaneous Immunotherapy ◽  
Perennial Allergic Rhinitis ◽  
Specific Igg4 ◽  
Immunological Changes

(1) Background: Biomarkers of efficacy for subcutaneous immunotherapy (SCIT) on allergic rhinitis have not been evaluated in details. The present study aims to assess the relevance of measuring of sIgE, sIgG4 and IgE/IgG4 ratio during SCIT in patients with allergic rhinitis; (2) Methods: 20 patients, 13 men and 7 women aged 19 to 58 years, with clinically manifested seasonal and perennial allergic rhinitis were studied. At the initiation and in the end of the three-year course of SCIT serum allergen-specific IgE and IgG4 were measured with ImmunoCAP system. The sIgE/sIgG4 ratio was calculated as a biomarker for immunologic effectiveness; (3) Results: There was a significant increase of sIgG4 antibodies (p < 0.05), while at the end of SCIT for the sIgE levels no significant changes were seen (p > 0.05). Moreover, 90% of patients showed a decrease of the IgE/IgG4 ratio; (4) Conclusions: In most of treated patients with AR, SCIT with Bulgarian allergen products leads to clear immunological changes. After a 3-year of SCIT there is a significant increase in allergen specific IgG4 levels and both decrease of sIgE and IgE/IgG4 ratio. sIgE, sIgG4 and IgE/IgG4 ratio can be used as a substantial biomarker for predicting immunological effectiveness of SCIT.

scholarly journals IgE, IgG1, and IgG4 Reactivity to Dermatophagoides pteronyssinus Glycosylated Extract in Allergic Patients

2019 ◽  
Vol 2019 ◽  
pp. 1-12 ◽  
Author(s):  
Rafael de Oliveira Resende ◽  
Leandro Hideki Ynoue ◽  
Juliana Silva Miranda ◽  
Karine Cristine de Almeida ◽  
Deise Aparecida de Oliveira Silva ◽  
...  
Keyword(s):  
Western Blotting ◽  
Specific Ige ◽  
Dermatophagoides Pteronyssinus ◽  
Cross Reactivity ◽  
House Dust Mites ◽  
Dust Mites ◽  
Specific Igg4 ◽  
Allergenic Proteins ◽  
Allergen Sources ◽  
Cona Affinity Chromatography

Background. House dust mites are important allergen sources and some of these allergenic proteins may contain carbohydrate moieties, which are able to be isolated using lectins, as Concanavalin A (ConA). This study aimed to investigate allergenicity (IgE) and antigenicity (IgG1 and IgG4) of ConA-unbound and ConA-bound Dermatophagoides pteronyssinus (Dpt) crude extracts using sera of mite-allergic patients as well as inhibition capacity of antibody binding. Material and Methods. We obtained mannose-enriched and mannose-depleted fractions from Dpt by ConA affinity chromatography. Both ConA-bound and ConA-unbound fractions were evaluated by ELISA and Western Blotting for specific IgE, IgG1, and IgG4 reactivity with sera obtained from 95 mite-allergic patients (DP+) and 92 nonallergic (NA) subjects. Inhibition ELISA was used to assess cross-reactivity between Dpt extract and its fractions. Results. Among the DP+ patients, no difference was found between ConA-unbound and ConA-bound fractions regarding the levels of specific IgE, IgG1, and IgG4. Nonallergic subjects had the same levels of specific IgG1 to both ConA-unbound and ConA-bound fractions, although for specific IgG4, values were higher for ConA-bound. A positive correlation was found among specific IgE, IgG1, and IgG4 levels when Dpt was compared to ConA-unbound and ConA-bound fractions. Recognition of crude Dpt by IgE, IgG1, and IgG4 was highly inhibited by ConA-unbound and ConA-bound fractions. Western Blotting revealed a broad spectrum of bands ranging from 14 to 116 kDa recognized by specific IgE and IgG4. However, IgG1 reached higher frequency values on high molecular weight polypeptides. Conclusion. ConA-unbound and ConA-bound fractions derived from D. pteronyssinus crude extract revealed important components involved in the IgE recognition in allergic patients as well as IgG1 and/or IgG4 in allergic and healthy subjects.

scholarly journals Low-dose sublingual immunotherapy compared to subcutaneous immunotherapy and conventional therapy in childhood asthma

2016 ◽  
Vol 44 (6) ◽  
pp. 243
Author(s):  
Ariyanto Harsono
Keyword(s):  
Childhood Asthma ◽  
Low Dose ◽  
Sublingual Immunotherapy ◽  
Disease Onset ◽  
Ethics Committee ◽  
Subcutaneous Immunotherapy ◽  
Control Group ◽  
High Dose ◽  
Treat Ment ◽  
Group A

Background Evidence begin to accumulate that high-dose sub-lingual immunotherapy (SLIT) is as effective as subcutaneousimmunotherapy (SIT) in the treatment of childhood asthma.Since the capacity of sublingual area is similar whether the doseis high or low, the efficacy of low dose may be important to bestudied.Objective To investigate the efficacy of low-dose sublingual im-munotherapy in the treatment of childhood asthma.Methods Parents signed informed consent prior to enrollment,after having received information about the study. Patients weremoderate asthma aged 6-14 years with disease onset of lessthan 2 years before the commencement of the study and peakexpiratory flow rate (PEFR) variability of more than 15%. Pa-tients were randomly allocated into group A, B, and C whoreceived subcutaneous immunotherapy, low-dose sublingualimmunotherapy, and conventional asthma therapy, respectively.Randomization was stratified into two strata according to agei.e., 6-11 years or 11-14 years. Patients of each stratum wererandomized in block of three for each group. At the end of threemonths, lung function tests were repeated. The primary outcomewas PEFR variability at the end of the study. The study wasapproved by the Ethics Committee of Soetomo HospitalSurabaya.Results Distribution of variants as represented by sex, age,eosinophil count, and total IgE concentration were normal inthe three groups. PEFR variability decreased significantly from16.97+0.81 to 8.50+5.08 and 17.0+0.87 to 8.40+4.72 in groupreceiving SIT and SLIT, respectively (p<0.05), but decreasednot significantly from 17.00+0.83 to 10.82+0.5.41 in control group(p>0.05).Conclusion Low-dose SLIT is as efficacious as SIT in the treat-ment of moderate asthma in children

scholarly journals The Influence of Monomer Composition and Surface-CrossLinking Condition on Biodegradation and Gel Strength of Super Absorbent Polymer

Polymers ◽  
2021 ◽  
Vol 13 (4) ◽  
pp. 663
Author(s):  
Jung Soo Kim ◽  
Dong Hyun Kim ◽  
Youn Suk Lee
Keyword(s):  
Treatment Time ◽  
Gel Strength ◽  
Control Group ◽  
Cellulose Content ◽  
Retention Capacity ◽  
Super Absorbent Polymer ◽  
Monomer Composition ◽  
Cellulose Hydrogel ◽  
Improved Performance ◽  
Absorbent Polymer

In this study, a superabsorbent polymer (SAP) comprising poly (IA-co-cellulose-co-VSA-co-AA; ICVA) core-SAP (CSAP) was synthesized through radical polymerization using itaconic acid (IA), acrylic acid (AA), cellulose, and vinyl sulfonic acid (VSA) as monomers. The absorption performances and relative biodegradability of various compositions prepared by adjusting the amounts of cellulose and VSA with constant IA and AA content were compared. Increasing the cellulose content in CSAP contributed to improved biodegradation of the surface-crosslinked SAP (SSAP) and gel strength, although the free absorbency (FA) and centrifuge retention capacity (CRC) decreased. Increasing the VSA content resulted in strong anionicity, which enables the absorption of large amounts of water. Surface-crosslinking technology was applied to the CSAP synthesized with the optimal composition ratio to increase its absorption performance and gel strength. Improved performance of the synthesized SSAP (a CRC of 30.4 g/g, absorbency under load (AUL) of 23.3 g/g, and permeability of 55 s) was achieved by selecting the optimal surface-crosslinking treatment time and the amount of distilled water in the surface-crosslinking solution: as the latter was increased in the surface-crosslinking solution, the AUL and permeability of the SSAP were improved, and its biodegradability was found to be 54% compared to the 100% biodegradable cellulose hydrogel in the control group.

Sign in / Sign up

Export Citation Format

Share Document